Reaffirming Buy on Boston Scientific: Strategic Pelvic Health Expansion and High-Growth Valencia Technologies Acquisition Support Upside Potential

Analyst Travis Steed from Bank of America Securities maintained a Buy rating on Boston Scientific and keeping the price target at $120.00.

Travis Steed has given his Buy rating due to a combination of factors tied to Boston Scientific’s strategic expansion in pelvic health and the growth prospects of the newly acquired Valencia Technologies. He views the eCoin implantable tibial nerve stimulator as a differentiated technology that fits well alongside BSX’s existing sacral neuromodulation portfolio, enabling a more complete set of treatment options for urinary urge incontinence in a largely underpenetrated market. Although there is some potential for overlap with current SNM therapies, Steed believes the competitive landscape and the need to match peers’ tibial offerings make this acquisition strategically sound, while also leveraging existing commercial call points and infrastructure.
Steed notes that the acquisition is expected to be immaterial to near-term EPS but additive to Boston Scientific’s weighted average medium-term growth rate, with Valencia projected to grow faster than the company’s overall portfolio. He highlights the anticipated double-digit revenue growth trajectory for eCoin, the attractive entry price given the limited number of strategic buyers in this niche, and the potential for a more pronounced revenue ramp as office reimbursement improves following a potential Category I code around 2028. He also points to favorable clinical data and a user-friendly device profile that can broaden BSX’s reach to patients who have not responded to or cannot tolerate more conservative treatments. Taken together, these strategic, financial, and clinical considerations support his decision to reaffirm a Buy rating and a price objective that implies meaningful upside from the current share price.

In another report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $115.00 price target.